Targeting NASH: THR-β, FXR, GLP-1R, and More
In March 2024, the U.S. FDA approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis).
Nonalcoholic steatohepatitis (NASH) presents a significant public health challenge. Several biomarkers and drug targets are known to be involved in NASH, and their dysregulation contributes to NASH pathogenesis. Sino Biological offers recombinant drug targets related to NASH to support the development of innovative therapies for NASH therapies and to address comorbidities such as diabetes.
Featured Products for NASH Drug Targets
Sino Biological has developed a panel of high-quality recombinant proteins for NASH drug targets, including FASN, THR-β, NR1H4/FXR, GLP-1R, PPARA, FGF19, FGF21, and ACLY. These proteins are HPLC-verified for high purity and are trusted by users as indicated by citations in top-tier journals. The antibodies for NASH drug targets are also available with a variety of applications, such as IHC-P, ICC/IF,WB, ELISA, and IP.
Learn more about drug targets for NASH.
Download poster to gain more valuable insights for NASH targets.
